Dysbiosis of the gut microbiota is a significant factor influencing the progression of hepatitis B-related cirrhosis (HBC). Bile acid (BA) metabolism is increasingly recognized as a key participant in the liver-gut microbiota axis. A total of 46 patients with HBC and 33 healthy adults were enrolled in this study. The HBC patients were divided into a BA-normal group and a BA-high group. Fecal samples were collected from patients under the conditions of their daily diet, and the 16 S rRNA test was performed for each sample. Compared with that in healthy adults, the alpha diversity of the gut microbiota in HBC patients significantly changed, with a decrease in beneficial microbiota and an increase in opportunistic pathogens. Notably, Bacilli, Enterobacteriales, Streptococcaceae, Veillonella and Lactobacillales were significantly increased in BA-high patients, whereas Clostridia and Clostridiales were significantly decreased. Akkermansiaceae abundance was reduced in the HBC group, and Lactobacillales was markedly enriched in HBC patients, with its abundance proportionally increasing with increasing BA. These findings provide critical insights for investigating the gut microbiota‒BA crosstalk in HBC, facilitating the discovery of novel biomarkers for disease monitoring and the development of microbiota-targeted therapeutic strategies modulating BA metabolism to intervene in HBC progression. This study was registered in the Chinese Clinical Trial Registry (ChiCTR2400090990) on October 17, 2024 (retrospectively registered).
Li et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: